Oral News and Research

RSS

More court hearings for health law legal challenges

This week, the Pacific Legal Foundation will make oral arguments in the U.S. Court of Appeals for the District of Columbia. Its challenge claims the health law imposes new taxes unconstitutionally.

7 May 2014

FDA accepts Merck's MK-3475 BLA for review

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for MK-3475, Merck's investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab.

6 May 2014

Nanoviricides develops new drug candidates against MERS infection

...

6 May 2014

Debiopharm signs new license and research agreement with Yale University

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, announced it has signed a new license and research agreement with Yale University (Yale), a premier university with a long tradition of basic and clinical biomedical research, regarding the discovery of MIF inhibitors for treatment of autoimmune and inflammatory diseases.

6 May 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.

6 May 2014

Kinex receives FDA allowance for Oratecan anti-cancer drug irinotecan with enhanced oral absorption

Kinex Pharmaceuticals, Inc. announced today that the United States Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for Oratecan, an oral form of an approved anti-cancer drug irinotecan with enhanced oral absorption.

6 May 2014

BeiGene receives $5M from Merck to develop BGB-283 BRAF inhibitor

BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development.

6 May 2014

New webcast for hepatitis receives accreditation by RCN Centre

Roche: The ‘Confronting the silent epidemic: clinical innovation forum’ webcast endorsed by HCV Action, British Liver Trust and the European Liver Patients Association, is now available for healthcare professionals (HCPs) to view on-demand.

5 May 2014

Research roundup: Compounding pharmacies; marketplace details; changes in insurance coverage

Outraged over a 2012 fungal meningitis outbreak traced back to Framingham, Massachusetts-based drug compounder New England Compounding Center (NECC) that left sixty-four people dead and more than 700 sickened, Congress passed the Compounding Quality Act .

5 May 2014

Vibrating oral capsule for chronic constipation shows positive results

An oral capsule that vibrates as it moves through the digestive tract has shown notable promise as a non-pharmacological treatment for constipation, according to new research presented today at Digestive Disease Week- (DDW).

5 May 2014

No increased HPV-linked oral cancer risk for long-term partners, says study

Partners of patients diagnosed with human papilloma virus (HPV)-positive oropharyngeal cancer (OPC) were no more likely to test positive for oral HPV infection than people in the general population, according to a study published in the April 28 online edition of the Journal of Clinical Oncology.

2 May 2014

Mayo Clinic neuroscientists define subtype of Alzheimer's disease

Neuroscientists at Mayo Clinic in Florida have defined a subtype of Alzheimer's disease (AD) that they say is neither well recognized nor treated appropriately.

2 May 2014

Study: Asthma is associated with reduced bone mineral density

Some of the 26 million Americans with asthma may also be prone to bone loss. According to a study published today in the May issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology, there seems to be association between asthma and a decrease in bone mineral density.

2 May 2014

LUNGevity Foundation welcomes FDA approval of Zykadia drug for advanced stages of lung cancer

LUNGevity Foundation applauds the FDA approval of Zykadia™ for the subset of anaplastic lymphoma kinase-positive (ALK+) patients with advanced cases of non-small cell lung cancer who have progressed on or are intolerant to crizotinib.

2 May 2014

$RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer$

RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer

Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

2 May 2014

Early gene therapy could improve choroideremia prognosis

Retinal gene therapy could prevent loss of vision in patients with choroideremia and other retinal diseases, show the results of a phase I/II study.

30 Apr 2014

Purdue Pharma seeks FDA authorization to market once-daily hydrocodone bitartrate tablet

Purdue Pharma L.P. announced that it has filed a New Drug Application (NDA) with the U.S. Food & Drug Administration seeking authorization to market a once-daily, single-entity hydrocodone bitartrate tablet (HYD).

30 Apr 2014

RDT receives FDA approval for new liquid form of treatment for patients with ALL

Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension---a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).

30 Apr 2014

Armetheon reaches agreement with FDA on SPA for final pivotal trial of tecarfarin

Armetheon, Inc., today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the final pivotal trial of tecarfarin.

29 Apr 2014

AAN review finds certain forms of medical marijuana can help treat some symptoms of MS

A review by the American Academy of Neurology of available scientific research on the use of medical marijuana in brain diseases finds certain forms of medical marijuana can help treat some symptoms of multiple sclerosis (MS), but do not appear to be helpful in treating drug-induced (levodopa) movements in Parkinson's disease.

29 Apr 2014

Oral News and Research

More court hearings for health law legal challenges

FDA accepts Merck's MK-3475 BLA for review

Nanoviricides develops new drug candidates against MERS infection

Debiopharm signs new license and research agreement with Yale University

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Kinex receives FDA allowance for Oratecan anti-cancer drug irinotecan with enhanced oral absorption

BeiGene receives $5M from Merck to develop BGB-283 BRAF inhibitor

New webcast for hepatitis receives accreditation by RCN Centre

Research roundup: Compounding pharmacies; marketplace details; changes in insurance coverage

Vibrating oral capsule for chronic constipation shows positive results

No increased HPV-linked oral cancer risk for long-term partners, says study

Mayo Clinic neuroscientists define subtype of Alzheimer's disease

Study: Asthma is associated with reduced bone mineral density

LUNGevity Foundation welcomes FDA approval of Zykadia drug for advanced stages of lung cancer

RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer

Early gene therapy could improve choroideremia prognosis

Purdue Pharma seeks FDA authorization to market once-daily hydrocodone bitartrate tablet

RDT receives FDA approval for new liquid form of treatment for patients with ALL

Armetheon reaches agreement with FDA on SPA for final pivotal trial of tecarfarin

AAN review finds certain forms of medical marijuana can help treat some symptoms of MS

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News